What would you like to look for?
Site search
Search filters

Inositec AG acquired by Vifor Pharma

Vifor Pharma acquires Zurich-based Inositec AG. Inositec develops first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.

RELIEF launches Level 1 ADR Program in the United States

RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company, has launched its Level 1 American Depositary Receipt ("ADR") program in the United States. As of 18 November 2021, ADRs may be traded over the counter.

CRK joins the MYTY Group

The full-service PR and communications agency cR Kommunikation AG with offices in Bern, Basel and Zurich has joined the MYTY Group, a leading agency network in the DACH region.

Nautilus acquires Swiss motion tech company VAY, in Zurich

Nautilus, Inc., an innovation leader in home fitness, has acquired Zurich based VAY AG, a leader in motion detection and analysis.

A fund advised by AFINUM Management AG buys GS Swiss PCB

A fund advised by AFINUM Management AG signed on 8 October 2021 a share purchase agreement with exceet Group AG, a company of the exceet Group, to buy exceet Group's portfolio company GS Swiss PCB AG.

EGO Movement and TVS Motor agree on a strategic partnership

The fast-growing Swiss e-mobility company EGO Movement (the GO AG) has agreed on a long-term strategic partnership with the leading Indian mobility group TVS Motor.

Novaremed acquires Metys Pharmaceuticals

Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.

Polyphor and EnBiotix sign merger agreement and sale of Murapavadin

Polyphor and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, have signed a merger agreement.

PDS Pathology Data Systems AG sold to Instem plc

Instem plc, a leading provider of IT solutions and services to the global life sciences market, has acquired its Swiss competitor PDS Pathology Data Systems AG, with offices in the United States and Japan, at an enterprise value of CHF 14.25m.

evitria Group sold to Atlas Antibodies, Sweden

The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies, Sweden. The transaction was completed on August 5, 2021.

You are currently offline. Some pages or content may fail to load.